Physician profile
Hannah E Bailey
NPI 1760190201
$2,165.29
in general payments reported to CMS, 2019-2025
24 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $694 · 2024: $995 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,165.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $438.39 | 2023-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $435.64 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $392.53 | 2023-2025 | |
| Lilly USA, LLC | $176.67 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $125.00 | 2023 | Dexcom G7 Gss (161) |
| Pfizer INC. | $110.21 | 2023-2025 | |
| Glaxosmithkline, LLC. | $85.94 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $48.90 | 2023-2024 | Freestyle Libre 3, Eterna |
| Sumitomo Pharma America, INC. | $41.62 | 2023 | Gemtesa |
| Organon LLC | $36.96 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.93 | 2023-2024 | Jardiance |
| Dynavax Technologies Corporation | $31.07 | 2024 | Heplisav-B |
| Verona Pharma, INC. | $26.39 | 2025 | Ohtuvayre |
| Tandem Diabetes Care, INC. | $21.49 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $19.06 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $17.12 | 2024 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $17.11 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.91 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $16.82 | 2024 | |
| Astellas Pharma US INC | $16.70 | 2024 | Veozah |
| Genzyme Corporation | $16.16 | 2023 | |
| Idorsia Pharmaceuticals US INC | $15.43 | 2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $13.64 | 2023 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $13.60 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.